Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 20/20 | 0.65 |
| ▸ | SRC | P12931 | 11/20 | 0.65 |
| ▸ | PDGFRB | P09619 | 7/20 | 0.65 |
| ▸ | PDGFRA | P16234 | 7/20 | 0.65 |
| ▸ | FGFR2 | P21802 | 6/20 | 0.58 |
| ▸ | FGFR4 | P22455 | 6/20 | 0.58 |
| ▸ | FGFR3 | P22607 | 6/20 | 0.58 |
| ▸ | EGFR | P00533 | 5/20 | 0.56 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.56 |
| ▸ | PRKCG | P05129 | 3/20 | 0.56 |
| ▸ | PRKCB | P05771 | 3/20 | 0.56 |
| ▸ | PRKCA | P17252 | 3/20 | 0.56 |
| ▸ | PRKCH | P24723 | 3/20 | 0.56 |
| ▸ | PRKCI | P41743 | 3/20 | 0.56 |
| ▸ | PRKCE | Q02156 | 3/20 | 0.56 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.56 |
| ▸ | PRKCZ | Q05513 | 3/20 | 0.56 |
| ▸ | PRKCD | Q05655 | 3/20 | 0.56 |
| ▸ | PRKD1 | Q15139 | 3/20 | 0.56 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2351653 | 0.95 | FGFR1 (0.63) | FGFR1SRCPDGFRBPDGFRAFGFR2 | |
| SCHEMBL465419 | 0.95 | FGFR1 (0.64) | FGFR1SRCPDGFRBPDGFRAFGFR2 | |
| SCHEMBL2355675 | 0.87 | FGFR1 (0.63) | FGFR1SRCPDGFRBPDGFRAFGFR2 | |
| SCHEMBL2349401 | 0.87 | FGFR1 (0.63) | FGFR1SRCPDGFRBPDGFRAFGFR2 | |
| SCHEMBL2355542 | 0.84 | FGFR1 (0.61) | FGFR1SRCPDGFRBPDGFRAFGFR2 | |
| SCHEMBL2347914 | 0.83 | FGFR1 (0.64) | FGFR1SRCPDGFRBPDGFRAFGFR2 | |
| SCHEMBL2354389 | 0.83 | FGFR1 (0.49) | FGFR1SRCPDGFRBPDGFRAFGFR2 | |
| SCHEMBL2355564 | 0.83 | FGFR1 (0.63) | FGFR1SRCFGFR2FGFR4FGFR3 | |
| SCHEMBL2348880 | 0.83 | FGFR1 (0.58) | FGFR1SRCPDGFRBPDGFRAFGFR2 | |
| SCHEMBL2352385 | 0.83 | FGFR1 (0.57) | FGFR1SRCPDGFRBPDGFRAFGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163522-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | SANOFI-AVENTIS (FR) | 2009-06-25 | — | — | US | claimed |
| US-7504406-B2 | Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same | SANOFI-AVENTIS (FR) | 2009-03-17 | — | — | US | claimed |
| US-20080176874-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | claimed |
| US-8008310-B2 | Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same | SANOFI-AVENTIS (FR) | 2011-08-30 | — | — | US | disclosed |
| US-20090163522-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | SANOFI-AVENTIS (FR) | 2009-06-25 | — | — | US | disclosed |
| US-7504406-B2 | Derivatives of pyrido[2,3-d]pyrimidine, the preparation thereof, and the therapeutic application of the same | SANOFI-AVENTIS (FR) | 2009-03-17 | — | — | US | disclosed |
| EP-1902054-B1 | DERIVATIVES OF PYRIDO[2,3-D]PYRIMIDINE, THE PREPARATION THEREOF AND THE THERAPEUTIC APPLICATION OF THE SAME | SANOFI AVENTIS (FR) | 2009-02-18 | — | — | EP | disclosed |
| EP-2020410-A1 | Pyrido[2,3d]pyrimidine derivatives, process for their preparation and their therapeutical use | sanofi-aventis (FR) | 2009-02-04 | — | — | EP | disclosed |
| US-20080176874-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | SANOFI-AVENTIS (FR) | 2008-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176874-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | DPYD, TYMP, TYMS | FGFR1 2373/4885SRC 2431/4885PDGFRB 432/4885 |
| US-20090163522-A1 | Derivatives of Pyrido[2,3-d]pyrimidine, the Preparation Thereof, and the Therapeutic Application of the Same | DPYD, TYMP, TYMS | FGFR1 2373/4885SRC 2431/4885PDGFRB 432/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.